Loading...

Purified anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
29F.1A12 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, Programmed Death-1, PDCD1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
29F-1A12_PURE_CD279_Antibody_102518
Con A and IL-2 stimulated mouse splenocytes (day 3) were stained with CD3ε APC and purified CD279 (clone 29F.1A12, left) or rat IgG2a, κ isotype control (right) followed by FITC anti-rat IgG.
  • 29F-1A12_PURE_CD279_Antibody_102518
    Con A and IL-2 stimulated mouse splenocytes (day 3) were stained with CD3ε APC and purified CD279 (clone 29F.1A12, left) or rat IgG2a, κ isotype control (right) followed by FITC anti-rat IgG.
  • 29F-1A12_PURE_CD279_Antibody_2_103018
    Fresh, frozen mouse spleen was stained with purified CD279 clone 29F.1A12 conjugated and detected with a Cy5 CODEX™ oligonucleotide duplex (red). Samples were counterstained with TCR FITC (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Cat # Size Price Quantity Check Availability Save
135202 500 µg 109€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F - Verified
Block - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Wang J, et al. 2017. Cancer Prev Res (Phila). 10:684. PubMed
  2. Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed
  3. Xie MM, et al. 2017. Eur J Immunol. 47:1136. PubMed
  4. Goel S, et al. 2017. Nature. 548:471. PubMed
  5. Shirakawa K, et al. 2017. PLoS One. 12:e0186303. PubMed
  6. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  7. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  8. Fiege JK, et al. 2019. PLoS Pathog. 15:e1008077. PubMed
  9. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
  10. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  11. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  12. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  13. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  14. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  15. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  16. Muhammad F, et al. 2020. Front Immunol. 975:11. PubMed
  17. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  18. Wang J, et al. 2021. Cancers (Basel). 13:. PubMed
  19. Morales-Molina A, et al. 2020. Cancers (Basel). 12:. PubMed
  20. Oba T, et al. 2021. J Immunother Cancer. 9:. PubMed
  21. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  22. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  23. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  24. Gilfillan CB, et al. 2020. Eur J Immunol. 50:505. PubMed
  25. Sato Y, et al. 2021. BMC Cancer. 21:1222. PubMed
  26. Flietner E, et al. 2022. Sci Rep. 12:10616. PubMed
  27. Son YM, et al. 2020. Eur J Immunol. 50:1067. PubMed
  28. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  29. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  30. Haque M, et al. 2021. Viruses. 13:. PubMed
  31. Imazeki H, et al. 2021. J Immunother Cancer. 9:. PubMed
  32. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  33. Wang M, et al. 2022. Front Pharmacol. 13:887457. PubMed
  34. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  35. Jiang W, et al. 2021. Sci Rep. 11:1864. PubMed
  36. Avalos A, et al. 2022. JCI Insight. 7: . PubMed
  37. Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed
  38. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  39. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  40. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  41. Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed
RRID
AB_1877121 (BioLegend Cat. No. 135202)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 5    Revision Date: 09/16/2020

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account